XML 46 R38.htm IDEA: XBRL DOCUMENT v3.25.3
Discontinued Operations - Schedule of Details of Loss from Discontinued Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenue     $ (121)  
Loss from discontinued operations, net of tax $ (3,003) $ (5,019) (21,452) $ (41,047)
SomaScan Business        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenue [1] 26,693 22,884 67,466 61,484
Cost of revenue 14,352 11,749 37,784 32,653
Gross profit 12,341 11,135 29,682 28,831
Selling, general and administrative expenses 8,474 9,937 25,573 43,280
Research and development 4,849 6,217 16,587 26,567
Transaction expenses [2] 2,203 0 12,710 0
Other (income) expense, net (181) 0 (3,578) 0
Total operating expenses 15,345 16,154 51,292 69,847
Loss from discontinued operations before income taxes (3,004) (5,019) (21,610) (41,016)
Income tax benefit (expense) 1 0 158 (31)
Loss from discontinued operations, net of tax $ (3,003) $ (5,019) $ (21,452) $ (41,047)
[1] During the three months ended September 30, 2025, the Company recognized revenue of $0.6 million related to the transaction price under the Collaboration Agreement with Illumina, which primarily reflects Illumina's initial exercise of its material right to be provided with SOMAmer reagents for commercialization of the co-branded kits. The Company has classified the $0.6 million within discontinued operations consistent with the treatment of all SomaScan Business-related activities. Out of the $0.6 million recognized, $0.1 million was released from the deferred revenue balance previously established under the Collaboration Agreement. See footnote 2 under the table below for more information related to the deferred revenue.
[2] Transaction expenses relate directly to costs attributable to the sale of the SomaScan Business.